drugset / Trial / NCT04617821
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2024-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Comparator | Irinotecan | Small molecule | — | Intravenous |
| Comparator | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Comparator | calcium formyl tetrahydrofolate | Unknown | — | Intravenous |
| Comparator | fluorouracil | Small molecule | — | Intravenous |